<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Atyr Pharma, Inc. — News on 6ix</title>
    <link>https://6ix.com/company/atyr-pharma-inc</link>
    <description>Latest news and press releases for Atyr Pharma, Inc. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 05 Mar 2026 05:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/atyr-pharma-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835498d78dffbe2df0e44d5.webp</url>
      <title>Atyr Pharma, Inc.</title>
      <link>https://6ix.com/company/atyr-pharma-inc</link>
    </image>
    <item>
      <title>aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update</title>
      <link>https://6ix.com/company/atyr-pharma-inc/news/atyr-pharma-announces-fourth-quarter-and-full-year-2025-results-and-provides-corporate-update-29</link>
      <guid isPermaLink="true">https://6ix.com/company/atyr-pharma-inc/news/atyr-pharma-announces-fourth-quarter-and-full-year-2025-results-and-provides-corporate-update-29</guid>
      <pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
      <description>Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod</description>
    </item>
    <item>
      <title>aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis</title>
      <link>https://6ix.com/company/atyr-pharma-inc/news/atyr-pharma-announces-scheduling-fda-130000517</link>
      <guid isPermaLink="true">https://6ix.com/company/atyr-pharma-inc/news/atyr-pharma-announces-scheduling-fda-130000517</guid>
      <pubDate>Tue, 03 Feb 2026 13:00:00 GMT</pubDate>
      <description>Meeting with the FDA to review the results from the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis is scheduled for mid-April 2026. SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the U.S. Food and Drug Administration</description>
    </item>
    <item>
      <title>aTyr Pharma to Present at Piper Sandler 37th Annual Healthcare Conference</title>
      <link>https://6ix.com/company/atyr-pharma-inc/news/atyr-pharma-present-piper-sandler-130000221</link>
      <guid isPermaLink="true">https://6ix.com/company/atyr-pharma-inc/news/atyr-pharma-present-piper-sandler-130000221</guid>
      <pubDate>Mon, 10 Nov 2025 13:00:00 GMT</pubDate>
      <description>SAN DIEGO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at the Piper Sandler 37th Annual Healthcare Conference, which is scheduled to take place December 2 – 4, 2025, in New York, NY. Details of the presentation appears</description>
    </item>
    <item>
      <title>aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update</title>
      <link>https://6ix.com/company/atyr-pharma-inc/news/atyr-pharma-announces-third-quarter-210100699</link>
      <guid isPermaLink="true">https://6ix.com/company/atyr-pharma-inc/news/atyr-pharma-announces-third-quarter-210100699</guid>
      <pubDate>Thu, 06 Nov 2025 21:01:00 GMT</pubDate>
      <description>Results reported for Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis. Company plans to meet with the FDA to determine path forward for efzofitimod in pulmonary sarcoidosis in the first quarter of 2026. Company expects to complete enrollment in Phase 2 EFZO-CONNECT™ study of efzofitimod in systemic sclerosis-related interstitial lung disease (SSc-ILD) in the first half of 2026. Ended the third quarter 2025 with $92.9 million in cash, cash equivalents, restricted cash and investmen</description>
    </item>
    <item>
      <title>aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update </title>
      <link>https://6ix.com/company/atyr-pharma-inc/news/atyr-pharma-announces-third-quarter-2025-results-and-provides-corporate-update</link>
      <guid isPermaLink="true">https://6ix.com/company/atyr-pharma-inc/news/atyr-pharma-announces-third-quarter-2025-results-and-provides-corporate-update</guid>
      <pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
      <description>Results reported for Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis. Company plans to meet with the FDA to determine path forward for</description>
    </item>
    <item>
      <title>aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT™ Study in Late-Breaking Oral Abstract at the European Respiratory Society (ERS) Congress 2025</title>
      <link>https://6ix.com/company/atyr-pharma-inc/news/atyr-pharma-presents-additional-findings-093000736</link>
      <guid isPermaLink="true">https://6ix.com/company/atyr-pharma-inc/news/atyr-pharma-presents-additional-findings-093000736</guid>
      <pubDate>Tue, 30 Sep 2025 09:30:00 GMT</pubDate>
      <description>Clinical benefit for efzofitimod across multiple disease-related health outcomes reported. Improvement in Fatigue Assessment Scale Total Score at week 48 observed in the 5.0 mg/kg efzofitimod treatment group vs placebo (p=0.0226). Improvement in King’s Sarcoidosis Questionnaire-General Health score at week 48 observed in the 5.0 mg/kg efzofitimod treatment group vs placebo (p=0.0197). SAN DIEGO, Sept. 30, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clin</description>
    </item>
    <item>
      <title>aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis</title>
      <link>https://6ix.com/company/atyr-pharma-inc/news/atyr-pharma-announces-topline-results-113000869</link>
      <guid isPermaLink="true">https://6ix.com/company/atyr-pharma-inc/news/atyr-pharma-announces-topline-results-113000869</guid>
      <pubDate>Mon, 15 Sep 2025 11:30:00 GMT</pubDate>
      <description>Study did not meet primary endpoint in change from baseline in mean daily oral corticosteroid (OCS) dose at week 48, although clinical benefit for efzofitimod observed across multiple study parameters. 52.6% of patients treated with 5.0 mg/kg efzofitimod achieved complete steroid withdrawal at week 48 vs 40.2% on placebo (p=0.0919). Clinical improvement in King’s Sarcoidosis Questionnaire (KSQ)-Lung score at week 48 observed in the 5.0 mg/kg efzofitimod treatment group vs placebo (p=0.0479). Gre</description>
    </item>
    <item>
      <title>aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
      <link>https://6ix.com/company/atyr-pharma-inc/news/atyr-pharma-announces-inducement-grants-200000634</link>
      <guid isPermaLink="true">https://6ix.com/company/atyr-pharma-inc/news/atyr-pharma-announces-inducement-grants-200000634</guid>
      <pubDate>Fri, 05 Sep 2025 20:00:00 GMT</pubDate>
      <description>SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compensation Committee of aTyr’s Board of Directors has granted three employees nonstatutory stock options to purchase an aggregate of 62,400 shares of aTyr’s common stock, each with an exercise price of $5.71 per</description>
    </item>
    <item>
      <title>aTyr Pharma Announces Second Quarter 2025 Results and Provides Corporate Update</title>
      <link>https://6ix.com/company/atyr-pharma-inc/news/atyr-pharma-announces-second-quarter-200000760</link>
      <guid isPermaLink="true">https://6ix.com/company/atyr-pharma-inc/news/atyr-pharma-announces-second-quarter-200000760</guid>
      <pubDate>Thu, 07 Aug 2025 20:00:00 GMT</pubDate>
      <description>Last patient visit completed in Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline results expected in mid-September 2025.SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced second quarter 2025 results and provided a corporate update. “With the recent co</description>
    </item>
    <item>
      <title>aTyr Pharma Announces Last Patient Visit in Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis</title>
      <link>https://6ix.com/company/atyr-pharma-inc/news/atyr-pharma-announces-last-patient-120000956</link>
      <guid isPermaLink="true">https://6ix.com/company/atyr-pharma-inc/news/atyr-pharma-announces-last-patient-120000956</guid>
      <pubDate>Tue, 22 Jul 2025 12:00:00 GMT</pubDate>
      <description>Topline results expected in the third quarter of 2025.SAN DIEGO, July 22, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the last patient has completed their last visit in the Company’s Phase 3 EFZO-FIT™ study of its lead therapeutic candidate, efzofitimod, in patients with pulmonary s</description>
    </item>
    <item>
      <title>aTyr Pharma to be Added to the Russell 2000® and Russell 3000® Indexes</title>
      <link>https://6ix.com/company/atyr-pharma-inc/news/atyr-pharma-added-russell-2000-120000192</link>
      <guid isPermaLink="true">https://6ix.com/company/atyr-pharma-inc/news/atyr-pharma-added-russell-2000-120000192</guid>
      <pubDate>Thu, 26 Jun 2025 12:00:00 GMT</pubDate>
      <description>SAN DIEGO, June 26, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Company is expected to be added to the Russell 2000® Index and broad market Russell 3000® Index, effective after the U.S. market close on June 27, 2025, as part of the 2025 Russell U.S. Indexes annual reconstitution</description>
    </item>
    <item>
      <title>aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)</title>
      <link>https://6ix.com/company/atyr-pharma-inc/news/atyr-pharma-announces-findings-interim-120000180</link>
      <guid isPermaLink="true">https://6ix.com/company/atyr-pharma-inc/news/atyr-pharma-announces-findings-interim-120000180</guid>
      <pubDate>Wed, 04 Jun 2025 12:00:00 GMT</pubDate>
      <description>Three out of four efzofitimod-treated diffuse SSc-ILD patients showed clinically important improvement based on the modified Rodnan Skin Score (mRSS) assessment at 12 weeks. Efzofitimod was generally safe and well tolerated at all doses. SAN DIEGO, June 04, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, to</description>
    </item>
    <item>
      <title>aTyr Pharma to Present at Upcoming Investor Conferences</title>
      <link>https://6ix.com/company/atyr-pharma-inc/news/atyr-pharma-present-upcoming-investor-120000868</link>
      <guid isPermaLink="true">https://6ix.com/company/atyr-pharma-inc/news/atyr-pharma-present-upcoming-investor-120000868</guid>
      <pubDate>Tue, 20 May 2025 12:00:00 GMT</pubDate>
      <description>SAN DIEGO, May 20, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at several upcoming investor conferences scheduled to take place in May and June 2025. Details of the conferences appear below: Conference: RBC Capital Markets Glob</description>
    </item>
    <item>
      <title> aTyr Pharma to Present at Upcoming Investor Conferences</title>
      <link>https://6ix.com/company/atyr-pharma-inc/news/atyr-pharma-to-present-at-upcoming-investor-conferences</link>
      <guid isPermaLink="true">https://6ix.com/company/atyr-pharma-inc/news/atyr-pharma-to-present-at-upcoming-investor-conferences</guid>
      <pubDate>Tue, 20 May 2025 04:00:00 GMT</pubDate>
      <description>SAN DIEGO, May 20, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development</description>
    </item>
    <item>
      <title>aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference</title>
      <link>https://6ix.com/company/atyr-pharma-inc/news/atyr-pharma-presents-three-posters-120000240</link>
      <guid isPermaLink="true">https://6ix.com/company/atyr-pharma-inc/news/atyr-pharma-presents-three-posters-120000240</guid>
      <pubDate>Mon, 19 May 2025 12:00:00 GMT</pubDate>
      <description>Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis largely balanced and representative of targeted trial population. Real-world evidence shows target market for efzofitimod in pulmonary sarcoidosis is higher than previously estimated with increased morbidity. Treatment practices in the U.S. show approximately 75% of diagnosed pulmonary sarcoidosis patients require treatment with steroids. SAN DIEGO, May 19, 2025 (</description>
    </item>
    <item>
      <title>aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis</title>
      <link>https://6ix.com/company/atyr-pharma-inc/news/atyr-pharma-advances-atyr0101-ind-120000382</link>
      <guid isPermaLink="true">https://6ix.com/company/atyr-pharma-inc/news/atyr-pharma-advances-atyr0101-ind-120000382</guid>
      <pubDate>Wed, 14 May 2025 12:00:00 GMT</pubDate>
      <description>Preclinical data demonstrate ATYR0101’s unique anti-fibrotic mechanism through interaction with LTBP-1. ATYR0101 to be showcased in oral presentation at the American Thoracic Society (ATS) 2025 Respiratory Innovation Summit. SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced</description>
    </item>
    <item>
      <title>aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update</title>
      <link>https://6ix.com/company/atyr-pharma-inc/news/atyr-pharma-announces-first-quarter-200100366</link>
      <guid isPermaLink="true">https://6ix.com/company/atyr-pharma-inc/news/atyr-pharma-announces-first-quarter-200100366</guid>
      <pubDate>Wed, 07 May 2025 20:01:00 GMT</pubDate>
      <description>Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis on track for the third quarter of 2025. Blinded baseline demographics and disease characteristics from Phase 3 EFZO-FIT™ study and current U.S. epidemiology and treatment practices for pulmonary sarcoidosis to be presented at ATS 2025. SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and developmen</description>
    </item>
    <item>
      <title>aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the American Association for Cancer Research (AACR) Annual Meeting 2025</title>
      <link>https://6ix.com/company/atyr-pharma-inc/news/atyr-pharma-presents-preclinical-data-120000528</link>
      <guid isPermaLink="true">https://6ix.com/company/atyr-pharma-inc/news/atyr-pharma-presents-preclinical-data-120000528</guid>
      <pubDate>Tue, 29 Apr 2025 12:00:00 GMT</pubDate>
      <description>Findings demonstrate ATYR2810’s anti-tumor activity and increased survival in a model of glioblastoma multiforme (GBM), a primary form of brain cancer.SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Company will present a poster featuring preclinical data for AT</description>
    </item>
    <item>
      <title>aTyr Pharma to Participate in April Investor Conferences</title>
      <link>https://6ix.com/company/atyr-pharma-inc/news/atyr-pharma-participate-april-investor-120000827</link>
      <guid isPermaLink="true">https://6ix.com/company/atyr-pharma-inc/news/atyr-pharma-participate-april-investor-120000827</guid>
      <pubDate>Thu, 03 Apr 2025 12:00:00 GMT</pubDate>
      <description>SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in two upcoming investor conferences scheduled to take place in April 2025. Details of the conferences appear below: Conference: Jones Healthcare and Technology Innovation Conference Date: April 8 – 9, 2025Location:</description>
    </item>
    <item>
      <title>aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise</title>
      <link>https://6ix.com/company/atyr-pharma-inc/news/atyr-pharma-announces-appointment-dalia-120000781</link>
      <guid isPermaLink="true">https://6ix.com/company/atyr-pharma-inc/news/atyr-pharma-announces-appointment-dalia-120000781</guid>
      <pubDate>Wed, 26 Mar 2025 12:00:00 GMT</pubDate>
      <description>SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise. Ms. Rayes brings over 25 years of experience building and leading commercial organizations at biotechnology and pharmaceutical companies</description>
    </item>
  </channel>
</rss>